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Bruton’s tyrosine kinase (Btk) is a signaling molecule involved in development and
activation of B cells through B-cell receptor (BCR) and Toll-like receptor (TLR)
signaling. We have previously shown that transgenic mice that overexpress human Btk
under the control of the CD19 promoter (CD19-hBtk) display spontaneous germinal
center formation, increased cytokine production, anti-nuclear autoantibodies (ANAs),
and systemic autoimsmune disease upon aging. As TLR and BCR signaling are
both implicated in autoimmunity, we studied their impact on splenic B cells. Using
phosphoflow cytometry, we observed that phosphorylation of ribosomal protein S6, a
downstream Akt target, was increased in CD19-hBtk B cells following BCR stimulation
or combined BCR/TLR stimulation, when compared with wild-type (WT) B cells. The
CD19-hBtk transgene enhanced BCR-induced B cell survival and proliferation, but had
an opposite effect following TLR9 or combined BCR/TLR9 stimulation. Although the
expression of TLR9 was reduced in CD19-hBtk B cells compared to WT B cells, a
synergistic effect of TLR9 and BCR stimulation on the induction of CD25 and CD80 was
observed in CD19-hBtk B cells. In splenic follicular (Fol) and marginal zone (MZ) B cells
from aging CD19-hBtk mice BCR signaling stimulated in vitro IL-10 production in synergy
with TLR4 and particularly TLR9 stimulation, but not with TLR3 and TLR7. The enhanced
capacity of CD19-hBtk Fol B cells to produce the pro-inflammatory cytokines IFNγ and
IL-6 compared with WT B cells was however not further increased following in vitro BCR
or TLR9 stimulation. Finally, we used crosses with mice deficient for the TLR-associated
molecule myeloid differentiation primary response 88 (MyD88) to show that TLR signaling
was crucial for spontaneous formation of germinal centers, increased IFNγ, and IL-6
production by B cells and anti-nuclear autoantibody induction in CD19-hBtk mice. Taken
together, we conclude that high Btk expression does not only increase B cell survival
following BCR stimulation, but also renders B cells more sensitive to TLR stimulation,
resulting in increased expression of CD80, and IL-10 in activated B cells. Although
BCR-TLR interplay is complex, our findings show that both signaling pathways are crucial
for the development of pathology in a Btk-dependent model for systemic autoimmune
disease.
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INTRODUCTION
B cells are crucial players in autoimmunity, as B cell depletion
therapy was proven effective in patients with several systemic
autoimmune diseases including Sjögren’s syndrome (SjS) and
rheumatoid arthritis (RA) (1, 2). These diseases are marked by
altered B cell selection leading to the production of autoreactive
antibodies, an important hallmark in the pathology of systemic
autoimmune diseases.
Signaling via the B cell receptor (BCR) is essential for B cell
survival (3). B cells are selected in the bone marrow (BM) at
the large pre-B cell and the immature B cell stage for functional
rearrangements of the immunoglobulin (Ig) heavy and light
chain genes, respectively. Subsequently, checkpoints follow to
select non-self-reactive B cells, both in the BM and in the
periphery where maturing B cells, referred to as transitional B
cells, undergo stringent selection. BCR signaling is crucial for
the selection of B cells. However, evidence is accumulating that
additional signals derived from CD40, Toll-like receptors (TLRs)
and BAFFR also affect selection of B cells (4).
A crucial signaling molecule in the development, survival and
activation of B cells is Bruton’s tyrosine kinase (Btk), a member
of the Tec family of non-receptor kinases. Btk is expressed in
almost all cells of the hematopoietic lineage, except T cells and
plasma cells (5, 6) and the expression of appropriate levels of Btk
is crucial for normal B cell development (7, 8). Functionally, Btk
is critically involved in many signaling pathways, such as BCR,
TLR, and chemokine receptor signaling (9). Patients with loss-
of-function mutations in the BTK gene present with X-Linked
agammaglobulinemia (XLA), an inherited immunodeficiency
marked by an almost complete arrest of B cell development at
the pre-B cell stage in the BM and a near absence of peripheral
B cells and circulating Ig (10, 11). In mice, Btk-deficiency does
not result in an arrest in B cell development in the BM, although
pre-B cell differentiation is somewhat impaired; due to a defective
transitional B cell maturation the numbers of peripheral B cells
are decreased (12–14). We have previously shown that BTK
protein levels are different across human peripheral blood B cell
subsets (15). Moreover, both in human and in mice BTK protein
levels are upregulated when mature B cells are activated in vitro
by various signals including those initiated by BCR, TLR, and
CD40 stimulation (8). Taken together, these findings demonstrate
the importance of Btk and indicate that its expression is tightly
regulated.
We have generated transgenic mice that overexpress human
Btk (hBtk) under the control of the CD19 promoter region
(CD19-hBtk). B cells from these mice show increased survival
and cytokine production and have the capacity to engage T cells
in spontaneous germinal center (GC) formation (8). CD19-hBtk
transgenic mice develop autoimmune pathology, characterized
by lymphocyte infiltrates in several tissues including salivary
glands and production of anti-nuclear autoantibodies (ANAs),
which was observed from the age of 25 weeks onwards (8). This
Btk-mediated autoimmunity phenotype is largely dependent on
interaction with T cells (16) and resembles human systemic lupus
erythematosus (SLE) and SjS. Human autoimmune disease is also
associated with increased BTK expression: we recently showed
that patients with RA and SjS have increased BTK protein levels
in B cells from peripheral blood, compared with healthy controls
(15). It remains unclear, however, whether the hBtk-mediated
autoimmune phenotype in the mouse strictly depends on BCR
signaling or on additional signaling pathways. The role of TLR
signaling in the development of autoimmune diseases has been
widely studied (17–25) and synergistic signaling of the BCR and
TLRs has been implicated in systemic autoimmune disease in
animal models (21, 26). Several lines of evidence indicate that Btk
is critically involved in this BCR-TLR synergy. Btk can directly
interact with the myeloid differentiation primary response 88
(MyD88) protein (27), an adaptor molecule downstream of
many TLRs. Interestingly, TLR9 stimulation appears to affect B
cell differentiation, as it was recently shown that engagement
of TLR9, which recognizes dsDNA, can antagonize antigen
processing and affinity maturation of antigen-specific B cells
(28). The relevance of Btk in TLR-mediated B cell activation
is supported by the finding that Btk-deficient B cells produced
less IL-10 upon TLR9 stimulation compared with B cells with
physiological Btk levels (29). In addition, Btk was shown to
mediate synergistic signaling between the BCR and TLR9 (30),
which is crucial for activation of autoreactive B cells (26).
Therefore, it is conceivable that BCR-TLR synergy contributes to
the initiation or maintenance of the autoimmune phenotype of
BTK-overexpressing transgenic mice.
In this report, we aimed to determine the contribution of TLR
signaling and BCR-TLR synergistic signaling to B cell activation
in our mouse model of Btk-mediated autoimmune disease.
Because the anti-dsDNA autoantibodies are prominent in aging
CD19-hBtk transgenic mice (8), we focused hereby on TLR9.
We first analyzed phosphorylation of various BCR and TLR
downstream signaling molecules in splenic B cells. Consistent
with increased survival of Btk-overexpressing B cells, when
compared with wild-type (WT) B cells, CD19-hBtk transgenic
B cells displayed increased phosphorylation of the ribosomal
protein S6 upon BCR stimulation. Although the expression of
TLR9 was reduced in CD19-hBtk B cells compared to WT B
cells, a robust synergistic effect of TLR9 and BCR stimulation
on S6 phosphorylation, CD25 and CD80 expression, and IL-
10 production was observed in CD19-hBtk B cells. Together
with the finding that TLR signaling was crucial for CD19-hBtk-
mediated autoimmunity in vivo, these results point to a role of




CD19-hBtk (31), Btk-deficient (12), and IgH.TEµmice (32) were
previously described. Myd88LSL/LSL (Myd88−/−) mice (33) were
crossed on CD19-hBtk mice to create the Myd88−/−CD19-hBtk
line. Mice were genotyped by PCR and MyD88-sufficient non-
hBtk transgenic littermates or C57/BL6 mice (Charles River)
were used as WT controls. Myd88−/− mice were crossed on
IgH.TEµ mice (>F3 sv129xC57BL/6) and onset of leukemia
was monitored every 3–6 weeks by peripheral blood screening
for monoclonal B cell expansion. Mice were bred and kept
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under specified pathogen-free conditions in the Erasmus MC
experimental animal facility. All experimental protocols were
reviewed and approved by the ErasmusMCCommittee of animal
experiments (DEC).
Flow Cytometry Procedures and Calcium
Influx
Cell suspensions of spleen and BM were obtained using 100µm
cell strainers in magnetic-activated cell sorting (MACS) buffer
(PBS/0.5% BSA/2mM EDTA), as previously described (16).
2 × 106 cells were incubated with varying combinations
of monoclonal antibodies (Table S1A) and stained according
to previously described procedures, whereby isotype and
fluorescence minus one (FMO) controls and non-expressing
cells were used to set-up and validate the staining procedures
(8). To stain for the isotype of intracellular immunoglobulins
(Ig) in plasma cells, cells were fixed with BD Cytofix/Perm
Buffer (BD Biosciences) and permeabilized with BD Perm/Wash
Buffer (BD Biosciences). The eBioscience FoxP3 staining
kit (eBioscience) was used to fix and permeabilize cells
to stain for FoxP3 expression. For intracellular staining
of cytokine-expressing cells, samples were fixed in PBS/2%
paraformaldehyde and permeabilized and stained in MACS
buffer containing 0.5% saponin (Sigma-Aldrich). For measuring
intracellular calcium mobilization, 5 × 106 splenocytes were
incubated with fluorogenic probes Fluo3-AM and Fura Red-
AM (Life Technologies), essentially as previously described
(34), except that we stained for B220+ splenocytes. Cell
cycle staining using propidium iodide (PI) was performed as
previously described (14). Leukemic B cells (CD19+CD5+) were
stained with FITC-labeled phosphatidylcholine (PtC) liposomes
(DOPC/CHOL 55:45, Formumax Scientific Inc.) in MACS
Buffer. All measurements were performed on an LSRII flow
cytometer (BD Biosciences) and results were analyzed using
FlowJo Version 9.7.6 software (TreeStar Inc).
Phosphoflow Cytometry
To determine phosphorylation of intracellular proteins 0.5–1 ×
106 cells were cultured in 2% FCS in RPMI at 37◦C for 5min
(pCD79a, pSyk and pPLCγ2) or for 3 h (pS6 and pAkt) with
20µg/mL anti-mouse antigen-binding F(ab′)2 -IgM fragments
(αIgM; Jackson ImmunoResearch), 2µM (for CD79a, pPLCγ2
and pAkt) or 0.1µM (pS6) CpG (ODN 1668; Invitrogen) or
combinations thereof prior to fixation with the eBioscience
FoxP3 staining kit Fix/Perm solution (eBioscience). Cells were
centrifuged and washed twice with eBioscience FoxP3 staining
kit Perm/Wash solution (eBioscience) and subsequently stained
for 30min at 4◦C with markers to identify B cells and T cells
(Table S1B), followed by staining for the appropriate phospho-
target (30min at RT). Cells stained for pS6 were subsequently
stained with anti-rabbit PE antibody (Jackson ImmunoResearch)
15min at RT. Isotype and FMO controls were included in the set-
up of the staining procedure, verifying the signal intensities of the
phospho-targets. In addition, non-expressing T cells were used
as internal controls for BCR-restricted signaling molecules in
all experiments. All measurements were performed on an LSRII
flow cytometer (BD Biosciences), and results were analyzed using
FlowJo Version 9.7.6 software (TreeStar Inc).
In vitro Stimulation for Cytokine Expression
To measure cytokine-expressing lymphocytes, splenic
cell suspensions were stimulated for 4 h at 37◦C using
50 ng/ml Phorbol 12-myristate 13-acetate (PMA) and
500 ng/ml ionomycin (both Sigma-Aldrich), 10µg/mL αIgM
(Jackson ImmunoResearch), 200µg/mL Poly:IC (Invivogen),
1.6µg/mL Lipopolysaccharide (LPS; Sigma-Aldrich), 40µg/mL
imidazoquinoline (Imiquimod VacciGradeTM; Invivogen),
and/or 2µM CpG (ODN 1668; Invitrogen) in combination with
monensin (Golgistop; BD Biosciences). To evaluate the effect of
Btk inhibition, 1µM ibrutinib (PCI-32765; Sigma-Aldrich) was
added to the in vitro cultures.
MACS Purification and in vitro B Cell
Cultures
Splenic cell suspensions from CD19-hBtk and WT control mice
were prepared inMACS buffer.MACS procedure and culture was
performed as previously published (8). Cells were stained with
biotinylated antibodies (Table S1C) followed by streptavidin-
coupledmagnetic beads (Miltenyi Biotec) and unlabeled naïve B2
cell fractions were collected by magnetic depletion of labeled cells
with a purity of >92%. Purified naïve B cells were stimulated for
48 h to evaluate cell cycle progression and 48 or 72 h for activation
markers with 10µg/mL αIgM (Jackson ImmunoResearch), 2µM
CpG (ODN 1668; Invitrogen) or combinations thereof in culture
medium (RPMI 1640/ 10% FCS/ 50µg/mL gentamycin/ 0.05mM
ß-mercaptoethanol). To evaluate the effect of Btk inhibition,
1µM ibrutinib (PCI-32765) was added to in vitro culture
conditions.
Immunohistochemistry
Myd88−/−CD19-hBtk, CD19-hBtk, and age-matched WT
control mice were sacrificed at 28–33 weeks of age. Salivary
glands and kidneys were collected, embedded in O.C.T-
compound (Sakura) and stored at−80◦C. Immunohistochemical
staining was performed as previously described (35). Slides were
washed with PBS and stained for 60min with anti-CD3
(eBioscience), anti-IgM or anti-IgG2c rat anti-mouse antibodies
(BD Biosciences), followed by a counterstaining with anti-
rat Alkaline Phosphatase (AP)-labeled antibodies (Jackson
ImmunoResearch). Anti-CD3-stained slides were stained for
60min with IgMFITC rat anti-mouse antibodies (BD Biosciences),
followed by counterstaining with streptavidin, anti-FITC or anti-
PE Peroxidase (PO)-labeled antibodies (Rockland). Slides were
embedded in Kaiser glycerol gelatin (Merck).
HEp-2 Reactivity Assay
Serum samples of 28–33 week-old mice (diluted 1:100 in
PBS) were incubated on HEp-2 slides (Bio-Rad Laboratories)
for 60min, as previously described (8). After washing with
PBS, slides were incubated with Alexa Fluor-488 conjugated
donkey anti-mouse IgM or IgG F(ab′)2 fragments (Jackson
ImmunoResearch) for 1 h. After washing and staining for
5min with DAPI, slides were embedded in VectaShield (Vector
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Laboratories). The LSM 510 META confocal fluorescence
microscope (Zeiss) was used to measure fluorescence intensity.
ELISA
Serum Ig subclasses were determined by sandwich ELISA. First,
plates were coated with unlabeled anti-IgM, anti-IgG1, and anti-
IgG2a (Southern Biotech) overnight at 4◦C. The next day, serum
and isotype standards (IgM, Bio-Rad; IgG1 and IgG2a, Southern
Biotech) were serially diluted and incubated at RT for 3 h.
This was followed by an incubation of 30min with biotinylated
IgM, IgG1, and IgG2a-specific antibodies (Southern Biotech) and
subsequently 30min of incubation with streptavidin peroxidase-
labeled antibodies (Jackson ImmunoResearch). Finally, we added
3, 3’,5, 5’- Tetramethylbenzidine (TMB) substrate (SeraCare) and
stopped the reaction by using sulfuric acid. Samples were read
at an OD of 450 nm using the VersaMax Microplate Reader
(Molecular Devices) to measure color intensity.
Line Immunoblot Assay (LIA) for
Extractable Nuclear Antigens
To measure extractable nuclear antigens, we used the INNO-
LIA R© ANA Update kit (Fujirebio) according to manufacturer’s
instructions. In short, LIA strips were incubated with serum
samples of 28–33 week-old mice [diluted 1:200 in sample
diluent (Fujirebio)] or with cut-off control containing
human IgG positive control antibodies. Next, LIA strips
were incubated with AP-labeled anti-mouse IgG antibodies
(Jackson ImmunoResearch). The cut-off control was incubated
with the supplied AP-labeled anti-human IgG antibodies
(Fujirebio). Finally, we added 5-bromo-4-chloro-3-indolyl
phosphate (BCIP)/nitro blue tetrazolium (NBT) substrate
(Fujirebio) diluted in substrate buffer and stopped the reaction
by adding sulfuric acid (Fujirebio). The LIA strips were removed
from the troughs and interpreted after they had completely
dried. As reference, LIA strips from samples were compared to
the supplied cut-off control and regarded positive when bands
were stained more intensely than the cut-off control.
Statistical Analysis
The non-parametric Mann-Whitney U test was used for
statistical analyses. Log Rank test was used to calculate the
significance for survival differences between indicated group of
mice for the chronic lymphocytic leukemia (CLL) experiments.
Differences between groups with P-values below 0.05 were
considered significant. Statistical analysis was performed using
GraphPad Prism 5 software (GraphPad Software Inc).
RESULTS
CD19-hBtk Transgenic B Cells Display
Increased Signaling of the Akt Pathway
Given the increased survival and activated phenotype of Btk-
overexpressing (CD19-hBtk) B cells (8, 15), we first studied
BCR signaling in splenic B cells from 8-week-old CD19-hBtk
mice. To this end, we stimulated total WT and CD19-hBtk
splenic cells with αIgM, the TLR9 ligand CpG, or combinations
thereof and determined the phosphorylation status of various
signaling molecules by phosphoflow cytometry analysis of gated
B220+CD3− B cells (Figure 1A; gating strategy in Figure S1A).
In these experiments, we used unstimulated gated B220+CD3− B
cells as a control.
Phosphorylation of Y182 in the ITAM of Ig-α/CD79a, the
transmembrane protein that forms a complex with the BCR, was
reduced in unstimulated CD19-hBtk B cells compared with WT
controls (Figure 1B). Expression of phosphorylated Y759 PLCγ2
(pPLCγ2) and Y348 Syk (pSyk) was similar in unstimulated
WT and CD19-hBtk B cells (Figure 1B). As expected, in WT
B cells phosphorylated CD79a (pCD79a) and pPLCγ2 were
induced upon αIgM stimulation (Figures 1A,B), but not upon
CpG stimulation for CD79a and pPLCγ2 (Figure S1B). Both
pCD79a and pPLCγ2 appeared somewhat reduced in αIgM-
stimulated CD19-hBtk B cells, although this was not significant.
BCR-induced pSyk was significantly reduced in CD19-hBtk B
cells when compared with WT B cells (Figure 1B).
TLR9-induced phosphorylation (S240/S244) of S6, a
ribosomal protein that is a downstream target of various signaling
cascades, including the Akt pathway, appeared unchanged in
CD19-hBtk B cells compared with WT controls (Figure 1C).
However, significantly increased pS6 was seen in CD19-hBtk B
cells upon BCR engagement alone or in combination with CpG
stimulation (Figure 1C). Phosphorylation of Akt at S473/T308
upon stimulation with αIgM or CpG was comparable between
CD19-hBtk and WT B cells, although CD19-hBtk B cells
showed reduced pAkt upon combined BCR-TLR stimulation
(Figure 1C). Taken together, these findings revealed limited
effects of TLR stimulation on the BCR signaling pathway,
whereas BCR stimulation induced S6 phosphorylation more
strongly in CD19-hBtk than in WT B cells.
In addition, we investigated the expression levels of TLR7 and
TLR9 protein as these TLRs are most relevant in the context of
autoimmune disease (17–19, 23). Expression of TLR7 was similar
in CD19-hBtk and WT splenic B cells ex vivo and following in
vitro αIgM stimulation (Figure 1D). In contrast, TLR9 protein
levels were decreased in CD19-hBtk B cells compared with WT
controls, both ex vivo and upon 48 h of in vitro stimulation with
αIgM (Figure 1E). This finding implies that CD19-hBtk and WT
may have a different responsiveness to TLR9 ligands.
BCR and TLR9 Signaling Differentially
Affect CD19-hBtk B Cell Proliferation and
Survival
To study whether TLR9 responsiveness alters BCR-mediated
activation of CD19-hBtk B cells, we MACS-purified naïve B
cells from spleens of 8-week-old CD19-hBtk and WT mice
and stimulated these fractions in vitro with αIgM, CpG, or a
combination thereof for 48 h to evaluate cell cycle progression
by PI staining. Consistent with our published findings (8),
these analyses showed that upon BCR stimulation survival
and proliferation was increased in B cells from CD19-hBtk
mice, compared with WT littermates (Figure 2A). This effect
was entirely dependent on Btk kinase activity, as the presence
of the Btk small molecule inhibitor ibrutinib completely
abrogated cellular proliferation in both WT and CD19-hBtk
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FIGURE 1 | Increased S6 phosphorylation upon BCR engagement in CD19-hBtk B cells. (A) Histogram overlays of representative examples of the phosphoprotein
analyses are shown for αIgM-induced induction of pCD79a, pSyk, pPLCγ2 and pS6, as well as CpG-induced pAkt. (B–C) Splenic cells of wild-type (WT) and
CD19-hBtk transgenic mice were stimulated for 5min (CD79a, Syk, and PLCγ2) or 3 h (S6 and Akt) and gated for B cells after the indicated in vitro stimulation. Fold
change (FC) increase of median fluoresence intensity (MFI) values compared to WT unstimulated are shown for phosphorylation of CD79a, Syk, PLCγ2 (B), and Akt
(C). Phosphorylation of ribosomal protein S6 was quantified using percentages of positive cells compared to unstimulated cells (C). (D,E) MFI values of TLR7 (D) and
TLR9 (E) protein in splenic B cells ex vivo and MFI FC induction of these TLRs on MACS-purified B cells after 48 h of stimulation with αIgM (dotted line indicates
expression in T cells). Symbols represent individual mice and bars indicate mean values. Graphs represent one to two individual experiments, each with 4–5 mice per
group; CD19-hBtk and WT mice were 8–10 weeks old; *p < 0.05, **p < 0.01 by Mann-Whitney U test.
αIgM stimulated B cells (Figure 2A). In contrast, in single
CpG-stimulation and combined αIgM/CpG-stimulation, Btk-
overexpressing B cells showed reduced proliferation, compared
with WT B cells (Figures 2B,C). This was dependent on Btk
kinase activity, as Btk inhibition essentially leveled-out the
differences between CD19-hBtk and WT B cells (Figures 2B,C).
Intriguingly, addition of ibrutinib decreased the proliferation
of CpG-stimulated WT B cells, suggesting that Btk kinase is
part of the signaling pathway downstream of TLR9 that induces
B cell proliferation. Therefore, both Btk inhibition and Btk
overexpression resulted in reduced B cell proliferation following
stimulation by CpG.
In summary, we found that Btk overexpression increases
survival and proliferative responses upon BCR engagement, but
limits the responsiveness to TLR9 stimulation.
The Activation Status of CD19-hBtk B Cells
Is Increased Following Combined BCR and
TLR9 Stimulation
Next, we tested activation marker upregulation of naïve B cells
of 8-week-old mice upon in vitro stimulation with αIgM, CpG,
and a combination thereof for 72 h. No major differences were
observed between WT vs. CD19-hBtk B cells in the upregulation
of CD86 expression (Figure 3A). In vitro stimulation with
CpG or αIgM resulted in an induction of CD25/IL-2R and
the costimulatory protein CD80 in B cells from both mouse
groups (Figures 3B,C). Combined stimulation of αIgM and
CpG decreased surface expression levels of CD86 and CD25
compared to αIgM alone, both in WT and in CD19-hBtk
B cells (Figures 3A,B), whereas this was not the case for
CD80 (Figure 3C). However, following CpG stimulation surface
expression of CD25 and CD80 was significantly increased on
CD19-hBtk B cells compared with WT B cells (Figures 3B,C).
Interestingly, in CD19-hBTK B cells but not in WT B
cells, simultaneous stimulation with CpG and αIgM resulted
in an additional increase in CD25 and particularly CD80
expression compared to CpG alone (Figure 3C). Expression
of the early activation marker CD69 was lower in CD19-
hBtk B cells, compared with WT B cells upon stimulation
with αIgM, CpG, or combined stimulation (Figure 3D). As
early activation marker CD69 is downregulated shortly after
its induction, it is conceivable that its reduced expression
on CD19-hBtk B cells resulted from rapid downregulation.
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FIGURE 2 | BCR and TLR9 stimulation have different effects on CD19-hBtk B cells. Proportions of B cells in apoptotic or cycling fractions, as determined by
propidium iodide (PI) DNA content staining of in vitro cultured purified naïve splenic B cells that were stimulated with 10 µg αIgM (A), 2µM CpG (B), or αIgM and CpG
combined (C), with or without ibrutinib (Ibr, 1µM) as indicated (left). Symbols represent individual mice and bars indicate mean values. Representative flow cytometry
graphs of WT and CD19-hBtk B cells are shown on the right, with the gating applied for apoptotic cells (sub-G1), resting cells (G0/G1), and dividing (S/G2/M) B cells.
CD19-hBtk and WT mice were 8–10 weeks old; n = 4–5 per group; *p < 0.05, **p < 0.01 by Mann–Whitney U-test.
Our finding of reduced CD69 expression would thus be
consistent with enhanced activation of CD19-hBtk B cells
following BCR or TLR9 stimulation. In these experiments, Btk
inhibition by ibrutinib affected BCR-induced but not TLR9-
induced changes in the expression of surface activation markers
(Figures 3A–D).
Therefore, we conclude that BCR and TLR9 signaling act
in synergy to induce a more activated surface phenotype in
Btk-overexpressing B cells.
IL-10-Production by CD19-hBtk B Cells Is
Synergistically Increased Following BCR
and TLR Stimulation
We have previously shown that autoimmune CD19-hBtk B
cells of 30-week-old (aged) mice have an enhanced capacity
to produce various cytokines, including IL-6, IL-10, and IFNγ
(16). Accordingly, stimulation with PMA/ionomycin increased
the proportions of IL-10-producing CD19-hBtk transgenic B
cells to higher levels than WT control B cells (Figure 4A). This
increase was observed in follicular (Fol) and marginal zone
(MZ) B cells, but not in splenic CD5+ B-1 cells, and was not
affected by the presence of ibrutinib (Figure 4B; gating strategy
in Figures S2A,B). To study B cell responsiveness to BCR and
TLR signaling with respect to IL-10 production, we stimulated
splenocytes from 30-week-old WT and CD19-hBtk mice with
αIgM, poly-IC (pIC; recognized by TLR3), LPS (recognized
by TLR4), Imiquimod (IMQ; TLR7), and CpG (TLR9), either
alone or in various combinations in the presence of golgistop
(monensin). In splenocyte cultures with monensin alone or with
αIgM very few B cells were positive for IL-10, as measured
by intracellular flow cytometry (Figure 4C). TLR stimulation
with LPS and particularly CpG resulted in a clear induction
of IL-10+ B cells specifically in CD19-hBtk mice (Figure 4C).
The proportions of IL-10+ CD19-hBtk B cells—but not WT
B cells—synergistically increased upon combined stimulation
of BCR/TLR4 and BCR/TLR9 (Figure 4C). Stimulation with
αIgM, together with TLR3 or TLR7 did not show a synergistic
effect. This capacity of transgenic Btk was largely dependent on
its kinase activity, because ibrutinib reduced IL-10 production
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FIGURE 3 | CD19-hBtk B cells show increased upregulation of activation markers upon synergistic BCR and TLR9 stimulation. Proportions of B cells positive for
CD86 (A), CD25 (B), CD80 (C), and CD69 (D) upon 72 h of stimulation of MACS-purified naïve splenic B cells with 10 µg αIgM (αIgM) and/or 2µM CpG, with or
without ibrutinib (Ibr, 1µM), as indicated (left). Symbols represent individual mice and bars indicate mean values. Representative histogram overlays are depicted on
the right. CD19-hBtk and WT mice were 8–10 weeks old; n = 4–5 per group; *p < 0.05, **p < 0.01 by Mann–Whitney U-test.
in response to TLR and BCR ligands nearly to WT levels
(Figure 4C).
Aged CD19-hBtk mice have increased numbers of splenic
CD5+ B-1 cells (8) and slightly decreased numbers of
Fol and MZ B cells, suggesting differential effects of Btk
overexpression on these B cell subpopulations. Therefore,
we investigated IL-10 production by splenic B cell subsets
separately. The proportions of IL-10+ Fol B cells were low
(Figure 4D). Nevertheless, we noticed that IL-10+ Fol B
cells were increased in CD19-hBtk mice upon stimulation
with CpG. Hereby, a synergistic effect was observed when B
cells were additionally stimulated with αIgM (Figure 4D).
MZ B cells of CD19-hBtk mice contained the highest
proportions of IL-10+ cells upon synergistic BCR and TLR9
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FIGURE 4 | Increased IL-10 expression following synergistic BCR and TLR9 stimulation of CD19-hBtk B cells. (A,B) Proportions of IL-10-expressing B cells after 4 h
of in vitro stimulation of total splenocytes from the indicated mice with PMA/ionomycin in the presence of monensin (golgi), as determined by intracellular flow
cytometry. Shown are data for gated total CD19+B220+CD3− B cells (A), or for gated B cell subpopulations (B), as indicated: follicular (Fol) B cells, marginal zone
(MZ) B cells and CD5+ B-1 cells. (C) Proportions of IL-10-expressing B cells after 4 h of in vitro stimulation of total splenocytes from the indicated mice with αIgM, the
indicated TLR ligands, or combinations thereof in the presence of monensin (golgi), as determined by intracellular flow cytometry. (D) Proportions of IL-10-expressing
B cells after 4 h of in vitro stimulation of total splenocytes from the indicated mice with αIgM (αIgM), CpG, or combinations thereof, with or without ibrutinib (Ibr, 1µM),
in the presence of monensin (golgi), as determined by intracellular flow cytometry. CD19-hBtk and WT mice were 28–33 weeks old. Symbols represent individual mice
and bars indicate mean values. Graphs represent two to three individual experiments; *p < 0.05, **p < 0.01, ***p < 0.001 by Mann–Whitney U-test.
stimulation (Figure 4D). We observed that splenic CD5+
B-1 cells from CD19-hBtk mice did not show substantial
differences, although significant, in proportions of IL-10+ cells,
when compared with CD5+ B-1 cells from WT littermates
(Figure 4D).
These data show that, compared to WT B cells, IL-10-
production is increased following synergistic BCR and TLR9
stimulation in CD19-hBtk Fol and MZ B cells, but not in CD5+
B-1 B cells. Hereby, CD19-hBtk transgenic MZ B cells have the
highest capacity to produce IL-10.
Increased IFNγ and IL-6 Production by
CD19-hBtk B Cells Reflects in vivo B Cell
Activation
Splenic B cells from aged CD19-hBtk mice have increased
proportions of IL-6+ and IFNγ+ cells upon stimulation with
PMA/ionomycin, compared to those from WT mice (16). A
separate analysis of splenic B cell subsets showed that the
increased IL-6+ and IFNγ+ production was present in CD19-
hBtk transgenic Fol and MZ B cells, but not in CD19-
hBtk transgenic CD5+ B-1 cells (Figure 5; gating strategy in
Figures S2A,B).Hereby, the proportions of IL-6+ or IFNγ+ cells
were larger in the MZ B cell than in the Fol B cell fractions. We
found that both for WT and for transgenic mice the proportions
of IL-6+ and IFNγ+ cells were quite similar in cultures with
monensin alone and in cultures stimulated by PMA/ionomycin
or αIgM, irrespective of the presence of ibrutinib (Figure 5).
Thus, addition of ibrutinib to these in vitro cultures did not
reduce the proportions of IL-6+ or IFNγ+ CD19-hBtk Fol or MZ
B cells to WT levels (Figures 5A,B,D,E).
In vitro CpG stimulation, either alone or in combination
with αIgM or ibrutinib had limited effects on IL-6+ or IFNγ+
production by Fol B cell or CD5+ B-1 cells (Figures 5A,C,D,F).
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FIGURE 5 | Analysis of IL-6 and IFNγ expression in B cell subsets from CD19-hBtk B cells. Proportions of IL-6+ (A–C) and IFNγ+ (D–F) B cells upon stimulation with
the indicated stimuli, with or without ibrutinib (Ibr, 1µM) in the presence of monensin (golgi), within gated B cell subsets: follicular (Fol) B cells (A,D), MZ B cells (B,E),
and CD5+ B-1 cells (C,F). CD19-hBtk and WT mice were 28–33 weeks old. Symbols represent individual mice and bars indicate mean values. Graphs are
representative for one to two individual experiments; *p < 0.05, **p < 0.01 by Mann–Whitney U-test.
In contrast, CpG stimulation increased the proportions of IL-
6+ cells by MZ B cells from both CD19-hBtk as WT mice,
to levels higher than in PMA/ionomycin cultures (Figure 5B).
Addition of ibrutinib in vitro did not appear to affect the
production of IL-6 by MZ B cells from either mouse group;
additional stimulation with αIgM reduced the frequencies of IL-
6+ cells, compared to CpG stimulation alone (Figure 5B). In
contrast to IL-6 production, we noticed that CpG stimulation
was associated with moderately reduced IFNγ production by
MZ B cells, irrespective of the presence or absence of ibrutinib
(Figure 5E).
In summary, the increase of the proportions of IFNγ+ and
IL-6+ cells within the B cell population present in the spleen of
CD19-hBtk mice could be attributed to Fol and MZ B cells and
not to CD5+ B-1 cells. This increase was largely independent
of in vitro stimulation and thus essentially reflected in vivo B
cell activation. Only IL-6 production by MZ B cells could be
enhanced in vitro by CpG stimulation.
Increased BCR Responsiveness in
CD19-hBtk B Cells Is Independent of
MyD88 Expression
To study whether TLR signaling is important for the
development of Btk-mediated autoimmune disease,
we crossed CD19-hBtk mice onto a MyD88-deficient
background and aged these mice to characterize their
phenotype. At ∼30 weeks of age, the total numbers of
Fol and MZ B cells in the spleen were decreased in both
CD19-hBtk and Myd88−/−CD19-hBtk mice, compared
to WT and Myd88−/− mice (Figure 6A). The absolute
numbers of CD5+ B-1 cells showed the converse and were
increased in CD19-hBtk and Myd88−/− CD19-hBtk mice
(Figure 6A).
When we investigated BCR responsiveness of total splenic B
cells of 8-week-old mice, we found that the prolonged calcium
influx and increased S6 phosphorylation upon αIgM stimulation
of CD19-hBtk B cells was MyD88-independent (Figures 6B,C).
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FIGURE 6 | Increased BCR responsiveness in CD19-hBtk B cells is independent of MyD88 expression. (A) Quantification of the absolute numbers of Fol B cells
(CD19+CD21−CD23+), MZ B cells (CD19+CD21+CD23−), and CD5+ B-1 cells (CD19highB220intCD5+) in spleens from the indicated aged mice. (B) Ca2+ influx
(Continued)
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FIGURE 6 | assay in B cells after stimulation with 25 µg F(ab’)2 anti-IgM in the indicated mouse groups. Data are representative for three mice analyzed.
(C) Representative histogram overlays of phosphorylated S6 (pS6) upon 20µg/mL αIgM or 2µM CpG stimulation in the indicated mouse groups. Data are
representative for two to three mice analyzed. (D) Representative histogram overlays of the expression of activation markers CD69, CD86, and CD25 in Myd88−/−
CD19-hBtk (red), CD19-hBtk (black), and WT mice (gray). Data are representative for two mice analyzed. (E) Proportions of B cells in apoptotic (left) or cycling (right)
fractions, as determined by PI staining for DNA content, after 2 days of in vitro stimulation with the indicated stimuli. CD19-hBtk and WT mice were 28–33 weeks old
(A) or eight weeks old (B–E). Data (mean values + SD) represent one to three individual experiments; *p < 0.05, **p < 0.01, ***p < 0.001 by Mann–Whitney U-test.
Myd88−/− CD19-hBtk B cells did not increase pS6 levels upon
CpG stimulation (Figure 6C), confirming that these cells were
TLR unresponsive. In addition, we noticed that the enhanced
upregulation of the cell surface markers CD69, CD86, and
CD25 upon αIgM stimulation was similar for CD19-hBtk and
Myd88−/− CD19-hBtk B cells (shown for 48 h; Figure 6D). Cell
cycle analysis by PI staining after 2 days of in vitro culture of
MACS-purified B cell fractions, in the presence or absence of
αIgM, revealed increased survival and proliferation of CD19-
hBtk B cells in a MyD88-independent manner (Figure 6E).
As expected, stimulation with LPS or CpG did not induce
proliferation in Myd88−/− and Myd88−/− CD19-hBtk B cell
fractions (Figure 6E).
Although we did not detect any effects of MyD88-deficiency
on αIgM-induced B cell proliferation and survival or expression
of activation markers in vitro, it cannot be excluded that
in an in vivo environment MyD88-deficiency may hamper
or augment BCR-dependent survival or proliferation signals.
Therefore, we investigated whether MyD88-deficiency would
influence leukemia development in our IgH.TEµ CLL mouse
model, in which we previously showed that (i) CLL development
is critically dependent on Btk and is accelerated in the
presence of the CD19-hBtk transgene, and that (ii) malignant
CLL B cells harbor high phosphorylation of Btk, Akt, and
S6 (34, 36). To this end, we crossed IgH.TEµ mice on
the Myd88−/− background. Monitoring for the presence of
increased frequencies of malignant CD5+ B cells in peripheral
blood (see Materials and Methods) revealed that IgH.TEµ
and Myd88−/− IgH.TEµ mice had a comparable incidence
of leukemic disease (Figure S3A). In addition, analysis of the
CLL cells for phosphatidylcholine (PtC)-specificity of the BCR,
indicative for a B-1 cell origin (37), showed that MyD88-
deficiency had no major effect on the usage of the PtC-specific
stereotypic BCR (Figure S3B).
From these in vitro and in vivo experiments, we conclude
that the BCR responsiveness of CD19-hBtk B cells is increased,
irrespective of the presence of MyD88.
MyD88 Is Indispensable for Btk-Mediated
Autoimmune Disease
Investigating autoimmune parameters in aged mice revealed
that CD19-hBtk mice had increased numbers of splenic GC
B cells, Fol helper T (Tfh) cells, and Fol regulatory T (Tfr)
cells compared to WT littermates (Figure 7A; gating strategy in
Figures S2A,C,D), as previously observed (8, 16). This increase
was fully dependent on MyD88 expression, asMyd88−/− CD19-
hBtk mice had splenic GC B cell, Tfh and Tfr numbers similar
to WT orMyd88−/− mice (Figure 7A). In addition, the increase
of IgM+, IgG1+, and less prominently, IgG2bc+ plasma cells
in the spleens of CD19-hBtk mice was MyD88-dependent
(Figure 7B; gating strategy in Figures S2A,E). IgM+ plasma
cells in the BM were also MyD88-dependently increased
(Figure S4A). IgG1+ plasma cells in BM were increased
in MyD88-deficient mice, as was previously described, and
increased further in Btk-overexpressing MyD88-deficient mice
(Figure S4A). Total serum IgM levels were not different between
the four groups of mice (Figure 7C). Likewise, the increased
numbers of IgG1+ plasma cells in the spleens of CD19-hBtk
mice was not reflected by increased total IgG1 concentrations
in the serum, compared with the three other groups of mice
(Figures 7B,C). We observed increased total IgG1 and decreased
IgG2c levels in the serum of Myd88−/− CD19-hBtk mice,
when compared with CD19-hBtk mice, which reflected the
numbers of plasma cells in BM rather than spleen (Figures 7B,C;
Figure S4A).
Next, we investigated the cytokine producing capacity of
splenic B and T cells. We observed that the increase of
the proportions of IL-6+ and IFNγ+ cells in the splenic B
cell populations of CD19-hBtk mice was MyD88-dependent
(Figure 7D). In contrast, the increase in IL-10+ B cells in CD19-
hBtk mice appears to be MyD88-independent (Figure 7D).
A separate analysis of Fol and MZ B cells showed that
the profiles for IFNγ+, IL-6, and IL-10 across the four
groups of mice were similar in the two B cell subsets (not
shown). For CD5+ B-1 we observed that the production of
the three cytokines was slightly reduced in CD19-hBtk mice,
in line with our findings described above (Figures 4, 5), as
well as in Myd88−/− CD19-hBtk mice (not shown). The
observed increase of cytokine production, including IFNγ+
and IL-10, by splenic T cells from in CD19-hBtk mice was
not observed in T cells from Myd88−/− CD19-hBtk mice
(Figure 7E).
Analysis of autoimmune pathology by immunohistochemistry
showed numerous perivascular B and T lymphocyte infiltrates in
the salivary glands of CD19-hBtk mice, which were completely
absent in Myd88−/− CD19-hBtk mice (Figure S4B), as well
as in WT and Myd88−/− mice (data not shown). MyD88
was also required for IgM+ or IgG2c+ glomerular immune
complex depositions in the kidneys, which were present
in CD19-hBtk but hardly in Myd88−/− CD19-hBtk mice
(Figure S4C). The production of IgM autoantibodies (mainly
cytoplasmic) and anti-nuclear IgG autoantibodies, as seen
in CD19-hBtk mice, was absent in Myd88−/− CD19-hBtk
mice (Figure 7F). It is of note that the anti-nuclear auto-
antibodies in CD19-hBtk mice were reactive to dsDNA and
chromatin (8, 16), RNA polymerase RNP-A, RNP-C, and Smith
antigen SmB (Figure S4D;Table S2), representing auto-antibody
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FIGURE 7 | MyD88 is required for Btk-mediated autoimmune disease. (A) Absolute numbers of splenic germinal center B cells (GC; CD19+ IgD−CD95+), Fol T
helper cells (Tfh; CD3+CD4+CXCR5+PD1+ FoxP3−) and Fol T regulatory cells (Tfr; CD3+CD4+CXCR5+PD1+ FoxP3+). (B) Absolute numbers of splenic IgM+,
IgG1+, and IgG2bc+ plasma cells (PC; CD11b− IgG1− IgGbc− IgM+CD138+, CD11b− IgG1+CD138+, and CD11b− IgG2bc+CD138+, respectively). (C) Serum
concentrations of IgM, IgG1, and IgG2c, as determined by ELISA. (D,E) IFNγ, IL-6, and IL-10 expression in gated B cell fractions (D) and CD3+CD4+ T cell fractions
(E) upon in vitro stimulation with PMA/ionomycin for 4 h in the presence of monensin. Symbols represent individual mice and bars indicate mean values. Graphs
represent two to three individual experiments. (F) Representative pictures of serum IgM (upper panel) and IgG (lower panel) reactivity with HEp-2 cells and
quantification of autoreactivity. Total number of mice analyzed are indicated within the pie charts; –, no staining; +/–, mild staining; +, moderate staining; ++, strong
staining. CD19-hBtk and WT mice were 28–33 weeks old; *p < 0.05, **p < 0.01, ***p < 0.001 by Mann–Whitney U-test.
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specificities that were shown to be dictated by TLR7 and
TLR9 (17).
Taken together, these data show that MyD88 is required for
the development of all hallmarks of autoimmune pathology in
CD19-hBtk mice with increased BCR responsiveness.
DISCUSSION
Btk is a critical kinase in the BCR signaling pathway and is
known to interact with various proteins that are downstream
of TLRs. The interplay between the BCR and TLR signaling
is thought to be crucial for the pathogenesis of autoimmune
disease. Our findings provide evidence that TLR signaling is
critical in systemic autoimmunity driven by overexpression of
Btk in transgenic mice, which is characterized by the induction of
TLR7/9-associated auto-antibody specificities, including dsDNA,
histone, RNP-A, RNP-C, and SmB.
Analysis of the functional consequences of BCR and TLR
stimulation in our CD19-hBtk mouse model revealed that
substantial complexity exists regarding the interplay of the two
signaling pathways. Btk overexpression amplified S6 signaling
in the context of IgM stimulation, but no effects were observed
on signaling levels upon TLR stimulation, even though we
detected decreased protein levels of TLR9 in CD19-hBtk B
cells compared to WT controls. In parallel, we found that
Btk overexpression increased survival and proliferation of B
cells when these were stimulated through BCR engagement,
but reduced proliferation after CpG or CpG/αIgM stimulation.
Nevertheless, using different functional readouts, clear additive,
or synergistic effects were observed. These include upregulation
of surface markers such as CD25, CD80, and CD86 and the
capacity of CD19-hBtk B cells to produce significantly increased
IL-10 levels after CpG stimulation, as compared to WT B
cells. Nevertheless, enhanced IL-10 expression was only seen
in Fol and MZ B cells and not in CD5+ B-1 cells. Along
these lines, we found that in aging CD19-hBtk mice Fol B
cells and CD5+ B-1 cells expressed increased levels of IL-
6 and IFNγ, but this was essentially not increased upon in
vitro stimulation with PMA/ionomycin, αIgM, or CpG. We also
noticed that TLR9 engagement by CpG increased the capacity
of MZ B cells to produce IL-6 to levels that were beyond
those reached by PMA/ionomycin stimulation. In contrast, CpG
stimulation of MZ B cells appeared to decrease their capacity
to produce IFNγ. Despite the observed complexity of TCR and
BCR interplay exposing both synergistic and opposite outcomes,
we established that MyD88-deficient CD19-hBtk transgenic mice
did not develop autoimmune symptoms. Therefore, we conclude
that TLR signaling is crucial for the induction of Btk-driven
autoimmune disease.
Various molecular mechanisms may connect Btk to both BCR
and TLR signaling. First, Btk is phosphorylated downstream of
the BCR and can directly interact with several components of the
TLR signaling pathway. These include the Toll/IL-1R homology
(TIR) domain, which is the intracellular signalingmodule of TLR,
the adapters MyD88 and MyD88 adapter-like (MAL) and IL-1R-
associated kinase-1 (IRAK-1) (9, 27). In particular, Kenny et al.
showed that Btk is essential for co-localization of the BCR and
TLR9 within an auto-phagosome-like compartment (30). The
authors found synergistic upregulation of activation markers,
which is in concordance with our findings. However, we did
not observe a kinase-independent role for Btk in synergistic IL-
6 production in response to CpG and αIgM in splenic B cells.
Second, upon BCR engagement Btk phosphorylates the B-cell
adaptor for phosphoinositide 3-kinase (BCAP), which provides
a binding site for PI3K (38). Interestingly, BCAP also links TLR
signaling to PI3K activation (39, 40) and contains a TIR domain,
which is used by TLR signaling adapters including MyD88. As
a result, it is conceivable that BCAP reduces the availability
of MyD88 for activation of NF-κB. Third, PLCγ2, which is a
direct substrate of Btk, can interact with another TIR-domain
containing adapter molecule, the B cell adaptor protein with
ankyrin repeats (BANK1) (41) which shows genetic association
with SLE in GWAS (42). BANK1 augments TLR7/TLR9 signaling
and was reported to control CpG-induced IL-6 secretion (43). B
cell IL-6 production, which can be enhanced by IFNγ, promotes
Tfh cell differentiation and initiates spontaneous GC formation
(44). Therefore, it is likely that increased IL-6 production by
Btk-overexpressing B cells is a major driver of autoimmunity in
CD19-hBTK mice. In our crosses with MyD88-deficient mice we
could show that enhanced expression of both IL-6 and IFNγ in
CD19-hBtk mice is TLR-dependent.
IL-10-producing B cells are important in autoimmune
diseases, as IL-10 is a proliferation factor for B cells and has
well-known regulatory functions (45–47). We observed that in
PMA/ionomycin stimulation experiments IL-10 production by
CD19-hBtk B cells was independent of MyD88 (Figure 7D) and
independent of CD40L expression (16). However, stimulation
with TLR ligands strongly induced IL-10-producing CD19-hBtk
B cells, but WT B cells showed low responsiveness. This is in
line with the previously reported finding that Btk is required
for TLR-induced IL-10 production by B cells (48, 49) and that
B cells from lupus-prone mice upregulate IL-10 production
in response to TLR stimulation, but not to BCR or CD40
engagement (50). Furthermore, we found that CD19-hBtk B
cells specifically increased IL-10 production upon combined
BCR-TLR stimulation over TLR stimulation alone, whereas this
remained unchanged in WT B cells. This finding demonstrates
that regarding IL-10 production autoimmune CD19-hBtk B cells
are very sensitive to dual ligation, which is in stark contrast with
the limited responsiveness of WT B cells.
We also found that all splenic B cell subsets produced IL-
10. Peritoneal CD5+ B-1 cells were previously shown to rely
on Btk for the production of IL-10, as B cells with low Btk
expression had decreased levels of IL-10 mRNA, compared with
B cells with physiological Btk levels (51). Although the number
of CD5+ B-1 cells is significantly increased in CD19-hBtk mice,
we did not observe increased proportions of IL-10+ cells within
the splenic CD5+ B-1 population in CD19-hBtk mice, compared
with WT. It was recently reported that Btk is not required
for the maintenance of the B-1 cell pool (52). Therefore, it is
very well-possible that Btk overexpression mainly affects the
generation of CD5+ B-1 cells during development and not the
IL-10 production by CD5+ B-1 cells in adult mice. The increase
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in IL-10 production and the synergistic responsiveness of CD19-
hBtk Fol and MZ B cells might point to an attempt of B cells to
control the autoimmune response, potentially via TLR9 signaling
(17, 23, 53). However, elevated IL-10 serum levels were found
in SLE patients with active disease (54), suggesting that IL-10-
producing autoimmune B cells could be disease-promoting, e.g.,
by the effects of IL-10 on B cell survival (45).
The increase in IFNγ+ and IL-6+ CD19-hBtk B cells upon
PMA/ionomycin stimulation was fully dependent on MyD88
expression and in vitro Btk inhibition for several hours did
not reduce IFNγ and IL-6 to WT levels. This suggests that in
vivo TLR-mediated B cell activation is crucial for the increase
in IFNγ+ and IL-6+ CD19-hBtk B cells. Further experiments
are required to identify the molecular mechanisms that are
responsible for the altered cytokine production capacity upon
long-lasting in vivo B cell activation, apparently resulting in
rewiring of signal transduction pathways and turning these B
cells refractory to Btk inhibition.
We demonstrated that TLR signaling is important in hBtk-
mediated autoimmune disease, although the in vitro BCR
responsiveness of CD19-hBtk B cells, including downstream
signaling, survival and proliferation, was enhanced in a MyD88-
independent fashion. However, spontaneous GC formation,
increased plasma cell differentiation, induction of Tfh cells,
increased production of IFNγ and IL-6, and the presence of
ANAs in serum, were clearly abrogated in the absence of MyD88.
It was recently reported that circulating chromatin in apoptotic
cell micro-particles induced SLE, which was dependent on
MyD88 expression (24). This suggests that autoreactive BCRs
bind chromatin in apoptotic material, providing a strong survival
signal by synergistic signaling with nucleic acid-sensing TLRs.
In addition, BCR-TLR synergism can drive AID expression
and thereby promote class-switching in T cell independent
responses (55). TLR signaling was also shown to be required
for amplification of GC responses, whereby B-cell-intrinsic
TLR responsiveness was upregulated during GC reactions (56),
implicating TLR signaling also in later stages of B cell activation
and differentiation.
Our findings demonstrate that enhanced BCR signaling
in CD19-hBtk B cells on its own is not sufficient for the
development of autoreactive responses. TLR expression in cell
types other than B cells could well-contribute to Btk-driven
autoimmunity, particularly because TLR signaling in dendritic
cells (DCs) and lymph node stromal cells is relevant for activation
of (autoreactive) B cells (22, 57, 58). Thus, the activation of
autoreactive B cells relies on TLR signaling in B cells and
potentially also in other cells, such as DCs and lymph node
stromal cells.
In summary, we have shown that TLR-mediated activation
is important for Btk-driven autoimmune disease, partly by
synergistically enhancing signaling responses of autoreactive
B cells. Next to mouse studies concerning Btk inhibition
in autoimmune diseases, currently clinical trials are ongoing
with several Btk inhibitors in autoimmune disease patients,
including RA (CC-292, HM71224, M2951, and GS-4059) and
SLE (BIIB068, MSC2364447C, and M2951) (www.clinicaltrials.
gov). Based on our current findings, together with the observed
increase in BTK protein expression levels in circulating B cells
from patients with RA and SjS (15), it is attractive to speculate
that Btk inhibition will dampen both BCR pathway activation
and synergistic BCR/TLR signaling in patients with systemic
autoimmune disease.
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